SCHACHLE JOSEPH K Insider Trading Activity (IRD)

Summary

Updated Jul 16, 2026

SCHACHLE JOSEPH K has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $44K.

Profile

Joseph K. Schachle serves as Chief Operating Officer of Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on inherited retinal diseases and other retinal disorders. In this role, he oversees operational strategy and execution to support the company’s AAV-based gene therapies and other ophthalmic programs. The SEC filing (CIK 0001145914) dated January 27, 2026 lists him as COO with no reported purchases or sales.

Role	Insider
Notability	40/100

Board memberships

Opus Genetics, Inc.

Awards & honors

Oversees operational strategy for clinical-stage ophthalmic programs
Supports scaling of manufacturing and supply chain to enable gene therapy development
Facilitates cross-functional collaboration among R&D, regulatory, and operations

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-04-27	IRD	Opus Genetics, Inc.	S — Open-market sale	4.7K	$5.22	$25K
2026-03-18	IRD	Opus Genetics, Inc.	S — Open-market sale	3.7K	$5.25	$20K
2026-01-27	IRD	Opus Genetics, Inc.	A — Grant or award	250.0K	$0.00

Frequently Asked Questions

Who is SCHACHLE JOSEPH K?

How many SEC Form 4 filings has SCHACHLE JOSEPH K submitted recently?

1 primary Form 4 filings in the last 90 days, covering 1 company.

Has SCHACHLE JOSEPH K been buying or selling stock?

Recorded transactions: 0 open-market purchases () and 2 open-market sales ($44K) across all tracked filings.

Where can I see all of SCHACHLE JOSEPH K's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

SCHACHLE JOSEPH K — SEC Form 4 Insider Trading Activity